Parkinson's disease and alpha-blocker

Predicting response to doxazosin in patients with voiding dysfunction and Parkinson's disease (PD): impact of the neurological impairment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46238855

Enrollment

Registered

2013-09-18

Start date

2005-08-25

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease (PD) and Bladder Outlet Obstruction (BOO) Nervous System Diseases Parkinson disease

Interventions

The severity of neurological impairment was assessed with the Unified Parkinson's disease rating scale. The assessment of this scale was performed by the referring neurologists and all patients on ant

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Idiopathic PD 2. Age above 40 years 3. Patients should have Bladder Outlet Obstruction (BOO), detrusor underactivity or an equivocal obstruction grade (Schafer zone II) associated with a post void residual volume > 150 ml. 4. Only patients with an abnormal voiding pattern in the pressure-flow study were included

Exclusion criteria

Exclusion criteria: 1. Patients with multiple system atrophy and other neurological conditions. 2. Subjects who used any bladder or prostate medications including alpha blockers, 5-alpha-reductase inhibitors or antimuscarinics for the past six months 3. Those with a history of pelvic or prostate surgery and/or radiotherapy

Design outcomes

Primary

Measure	Time frame
Treatment success (responder) was defined as an improvement of more than or equal to 50% of the LUTS, as measured by the ICSmSF questionnaire.	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Brazil

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026